Literature DB >> 8453965

Steady-state pharmacokinetics of methadone in opioid addicts.

K Wolff1, A W Hay, D Raistrick, R Calvert.   

Abstract

Kinetic parameters were investigated in tolerant methadone maintenance patients. The disposition of methadone at steady-state was assessed on 8 occasions-in 5 opioid addicts prescribed wide ranging doses of methadone (10 mg to 60 mg per day)-providing unique pharmacokinetic data. Statistical analysis showed that the kinetics of oral methadone at steady-state were described using a single compartment model. Analysis of the plasma concentration-time curves gave estimates of the variance of methadone clearance and apparent volume of distribution, and indicate that methadone is rapidly absorbed (mean Ka, 1.7 h-1) with a detectable increase in the plasma drug concentration 15 to 30 min after dosing. The elimination of methadone from plasma was found to occur slowly (mean t1/2 26.8 h) beginning soon after the administration of the daily oral prescription. The apparent volume of distribution-assuming the oral bioavailability (f) of methadone to be 0.95--was large (mean 6.7 l.kg-1). The slow clearance of this drug from the body (mean 3.1 ml.min-1.kg-1) confirms that daily dosing at steady-state is adequate to maintain effective plasma concentrations throughout the dosing interval.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453965     DOI: 10.1007/bf00315479

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

Authors:  K Verebely; J Volavka; S Mulé; R Resnick
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

2.  Blind comparison of once-daily and twice-daily dosage schedules in a methadone program.

Authors:  A Goldstein
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

3.  The levels of methadone in the plasma in methadone maintenance.

Authors:  C E Inturrisi; K Verebely
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

Review 4.  Implications of methadone maintenance for theories of narcotic addiction.

Authors:  V P Dole
Journal:  JAMA       Date:  1988-11-25       Impact factor: 56.272

5.  Disposition of methadone in methadone maintenance.

Authors:  E Anggård; L M Gunne; J Homstrand; R E McMahon; C G Sandberg; H R Sullivan
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

6.  Estimation of methadone clearance: application in the management of cancer pain.

Authors:  J L Plummer; G K Gourlay; D A Cherry; M J Cousins
Journal:  Pain       Date:  1988-06       Impact factor: 6.961

7.  Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain.

Authors:  C E Inturrisi; W A Colburn; R F Kaiko; R W Houde; K M Foley
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

8.  Metabolic interactions between opiates and alcohol.

Authors:  M J Kreek
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

9.  Phenytoin-induced methadone withdrawal.

Authors:  T G Tong; S M Pond; M J Kreek; N F Jaffery; N L Benowitz
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

10.  Methadone concentrations in plasma and their relationship to drug dosage.

Authors:  K Wolff; M Sanderson; A W Hay; D Raistrick
Journal:  Clin Chem       Date:  1991-02       Impact factor: 8.327

View more
  15 in total

1.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

2.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

3.  Methadone maintenance and tuberculosis treatment.

Authors:  D Raistrick; A Hay; K Wolff
Journal:  BMJ       Date:  1996-10-12

Review 4.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Methadone for Pain Management: A Pharmacotherapeutic Review.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

Review 6.  Pharmacogenomics of methadone: a narrative review of the literature.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Nicole Horn; Brian R Overholser; Sara K Quinney; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2020-07-24       Impact factor: 2.533

7.  Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study.

Authors:  Gavin Bart; Scott Lenz; Robert J Straka; Richard C Brundage
Journal:  Drug Alcohol Depend       Date:  2014-10-24       Impact factor: 4.492

8.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.